Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
DAPTOMYCIN (DAPTOMYCIN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
DAPTOMYCIN
NDA
Get alerts
DAPTOMYCIN | N210282 | HOSPIRA INC
2 strengths
2 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
2 unique patents by expiration date
All strengths
350MG/VIAL
500MG/VIAL
Active (2)
Today
2027
2028
2029
2030
2031
2032
2033
2034
Today
9655946
Sep. 11, 2033
10357535
Sep. 11, 2033
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 350MG/VIAL
RLD
2 patents
0 exclusivities
▴
POWDER;INTRAVENOUS | Approved: Jun 21, 2021
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9655946
Sep 11, 2033
—
—
Yes
U-3175
TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
—
10357535
Sep 11, 2033
—
—
Yes
U-3176
TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
—
#002 — 500MG/VIAL
RLD
2 patents
0 exclusivities
▾
POWDER;INTRAVENOUS | Approved: Jun 21, 2021